Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment

This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: Bexagliflozin; Drug: Placebo

Detailed Description

The phase 3, double-blind, placebo-controlled parallel-group study was conducted at investigative sites in the US, Japan, France and Spain. Approximately 300 subjects were to be randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in equal ratio for 24 weeks.

The study was to enrolled male and female participants who had T2DM with an HbA1c between 7.0 and 10.5% (inclusive) and stage 3 chronic kidney disease (CKD) as defined by an eGFR of ≥ 30 and< 60 mL min-1 per 1.73 m2 at the screening visit and one additional time of measurement between 1 and 12 months prior to screening. Subjects were either treatment naïve or were treated with a stable regimen of anti-diabetic medications.

All eligible subjects were to enter a one-week single-blind, placebo run-in period. Subjects who were compliant in taking run-in medication, had screening eGFR ≥ 30 and< 60 mL min-1 per 1.73 m2, and had stable GFR (no more than 20% change in eGFR between a historical value and the value determined at the screening visit) were eligible for randomization. Randomization was stratified by HbA1c level (7.0 to 8.5% or 8.6 to 10.5%), anti-diabetic treatment regimen and eGFR (30 - 44 mL min-1 per 1.73 m2 or 45 - 59 mL min-1 per 1.73 m2). At least 135 subjects in each of the eGFR groups were planned.

Study subjects were to schedule clinic visits at weeks 2, 6, 12, 18, and 24 for safety and efficacy evaluation. At weeks 2 and 18, the visits were to be conducted via phone interviews unless an in-person visit was considered clinically advisable. A final follow-up visit was to be conducted at week 26 or two weeks after the last dose of investigational product if the subject withdrew prior to week 24.

• Study Type: Interventional
• Enrollment (Actual): 312
• Phase: Phase 3

Contacts and Locations

Study Locations

• France
  • Dijon, France, 21079
    • Research Site
  • Paris, France, 75010
    • Research Site
  • Paris, France, 75013
    • Research Site
  • Paris, France, 75877
    • Research Site
  • Pierre Benite, France, 69310
    • Research Site
  • Poitiers, France, 86021
    • Research Site
  • Venissieux, France, 69200
    • Research Site
• Japan
  • Kanagawa
    • Atsugi-shi, Kanagawa, Japan, 243-0035
      • Research Site
    • Kamakura-shi, Kanagawa, Japan, 247-0056
      • Research Site
    • Kawasaki-shi, Kanagawa, Japan, 210-0852
      • Research Site
    • Yokohama-shi, Kanagawa, Japan, 231-0023
      • Research Site
    • Yokohama-shi, Kanagawa, Japan, 221-0802
      • Research Site
    • Yokohama-shi, Kanagawa, Japan, 241-0821
      • Research Site
  • Kyoto
    • Kyoto-shi, Kyoto, Japan, 600-8898
      • Research Site
    • Kyoto-shi, Kyoto, Japan, 615-8125
      • Research Site
  • SAitama
    • Sayama-shi, SAitama, Japan, 350-1305
      • Research Site
  • Saitama
    • Kawagoe-shi, Saitama, Japan, 350-0851
      • Research Site
    • Kawaguchi-shi, Saitama, Japan, 332-0021
      • Research Site
  • Tokyo
    • Hachioji-shi, Tokyo, Japan, 192-0918
      • Research Site
    • Hachioji-shi, Tokyo, Japan, 193-0811
      • Research Site
    • Minato-ku, Tokyo, Japan, 108-0075
      • Research Site
    • Ota-ku, Tokyo, Japan, 143-0015
      • Research Site
    • Shinagawa-ku, Tokyo, Japan, 141-0032
      • Research Site
  • Toyko
    • Toshima-ku, Toyko, Japan, 171-0021
      • Research Site
• Spain
  • Alcala de Henares, Spain, 28805
    • Research Site
  • Alicante, Spain, 03004
    • Research Site
  • Madrid, Spain, 28009
    • Research Site
  • Madrid, Spain, 28006
    • Research Site
  • Malaga, Spain, 29010
    • Research Site
  • Malaga, Spain, 29009
    • Research Site
  • Sevilla, Spain, 41009
    • Research Site
  • Valencia, Spain, 46026
    • Research Site
  • Valencia, Spain, 46600
    • Research Site
• United States
  • California
    • Fresno, California, United States, 93720
      • Research Site
    • La Palma, California, United States, 90623
      • Research Site
    • Lincoln, California, United States, 95648
      • Research Site
    • Riverside, California, United States, 92505
      • Research Site
    • Sacramento, California, United States, 95825
      • Research Site
    • San Dimas, California, United States, 91773
      • Research Site
  • Colorado
    • Monument, Colorado, United States, 80132
      • Research Site
  • Connecticut
    • Norwalk, Connecticut, United States, 06851
      • Research Site
  • Florida
    • Hollywood, Florida, United States, 33024
      • Research Site
    • Tampa, Florida, United States, 33607
      • Research Site
    • West Palm Beach, Florida, United States, 33401
      • Research Site
  • Kentucky
    • Paducah, Kentucky, United States, 42003
      • Research Site
  • Maine
    • Auburn, Maine, United States, 04210
      • Research Site
    • Rockport, Maine, United States, 04856
      • Research Site
  • New Hampshire
    • Nashua, New Hampshire, United States, 03063
      • Research Site
  • New York
    • Bronx, New York, United States, 10461
      • Research Site
  • Ohio
    • Stow, Ohio, United States, 44224
      • Research Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • Research Site
  • Texas
    • Austin, Texas, United States, 78731
      • Research Site
    • Austin, Texas, United States, 78758
      • Research Site
    • North Richland Hills, Texas, United States, 76180
      • Research Site
    • Round Rock, Texas, United States, 78681
      • Research Site
    • San Antonio, Texas, United States, 78229
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Each subject was required to meet the following criteria at the time of enrollment to be eligible for the study:

1. To have been male or non-pregnant female ≥ 20 years of age. Women of childbearing potential were required to agree to use contraception throughout the study to avoid any possible pregnancy. Females who were surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses for greater than 12 months and age > 45 years) were eligible if they tested negative on the urine pregnancy test.
2. To have had a diagnosis of T2DM with an HbA1c between 7.0 and 10.5% (inclusive) at the time of screening.
3. To have been treatment naïve or to have been treated with a stable regimen of anti-diabetic medications. At the time of screening, the doses and frequency of all anti-diabetic medications were to have been stable for 8 weeks.
4. To have had an eGFR ≥ 30 and < 60 mL min-1 per 1.73 m2 at 2 time points: screening (V1), and 1 additional time point between 1 and 12 months of screening (may be obtained from available medical records). The eGFR was calculated by the MDRD equation.
5. To have had a body mass index (BMI) ≤ 45 kg per m2 (inclusive).
6. To have been taking stable doses of medications for hypertension or hyperlipidemia (if applicable) for at least 30 days prior to randomization
7. To have had stable eGFR between the historic value and day of screening (no more than 20% change in eGFR between the most recent historical value and the value determined at the screening visit V1).

9.3.2 Exclusion Criteria

Potential participants who exhibited any of the following characteristics were excluded from the study:

1. A diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young (MODY)
2. A hemoglobinopathy that could affect HbA1c measurement
3. Frequent symptomatic hypoglycemia (greater than one episode per week on average)
4. A history of genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months
5. A cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix were not grounds for exclusion)
6. A history of alcohol or illicit drug abuse in the past 2 years
7. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
8. A history of MI, stroke or hospitalization for heart failure, or hospitalization for unstable angina in the prior 3 months
9. Evidence of NYHA class IV heart failure at screening or randomization
10. A history of taking an SGLT2 inhibitor within 3 months of screening
11. Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment
12. A current status of pregnancy or breastfeeding
13. A current status of renal replacement therapy (peritoneal or hemodialysis) or a history of renal transplantation
14. A corrected serum calcium < 8 mg dL-1 at screening (V1) or randomization (V3)
15. Uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >110 mm Hg)
16. Participation in another interventional trial or exposure to an investigational drug within 30 days or 7 half-lives of screening, whichever was longer
17. Previous exposure to bexagliflozin or EGT0001474
18. Evidence of having skipped dosing more than once during the run-in period
19. A fasting blood glucose value during the run-in period ≥ 250 mg dL-1 (13.9 mmol L-1) associated with severe clinical signs or symptoms of hyperglycemia
20. Any episode of symptomatic hypoglycemia during the run-in period in which symptoms were severe
21. An inability to comprehend or unwillingness to provide written informed consent in accordance with institutional and regulatory guidelines

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Bexagliflozin tablets, 20 mg; Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.	Drug: Bexagliflozin; Bexagliflozin tablet, 20 mg; Other Names: EGT0001442; EGT0001474
Placebo Comparator: Placebo tablets; Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.	Drug: Placebo; Placebo (inactive) tablet to match the active comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in HbA1c at 24 Weeks	The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with moderate renal impairment.	24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Body Weight From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2	A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in BMI from baseline to week 24 in subjects with a BMI ≥ 25 kg/m2.	24 weeks
Change From Baseline in Systolic Blood Pressure (SBP) in Subjects With Baseline SBP ≥ 130 mm Hg at Week 24	A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change from baseline in SBP to in subjects with baseline SBP ≥ 130 mm Hg at Week 24.	24 weeks
Change From Baseline in HbA1c in Subjects With Stage 3a CKD (eGFR 45 to 59 mL/Min/1.73 m2) at Week 24	A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3a CKD (eGFR 45 to 59 mL/min/1.73 m2) at week 24.	24 weeks
Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24	A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3b CKD (eGFR 30 to 44 mL/min/1.73 m2) at week 24.	24 weeks

Collaborators and Investigators

• Sponsor: Theracos
• Investigators: Study Director: Andrew Allegretti, M.D., Massachusetts General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 23, 2016
• Primary Completion (Actual): January 11, 2018
• Study Completion (Actual): January 11, 2018

Study Registration Dates

• First Submitted: July 14, 2016
• First Submitted That Met QC Criteria: July 14, 2016
• First Posted (Estimate): July 19, 2016

Study Record Updates

• Last Update Posted (Actual): June 30, 2021
• Last Update Submitted That Met QC Criteria: June 28, 2021
• Last Verified: June 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Bexagliflozin
• Other Study ID Numbers: THR-1442-C-448

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No